Frazier Life Sciences Management L.P. Grows Stock Holdings in Immatics (NASDAQ:IMTX)

Frazier Life Sciences Management L.P. grew its stake in shares of Immatics (NASDAQ:IMTX - Free Report) by 58.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 2,147,911 shares of the company's stock after acquiring an additional 793,200 shares during the quarter. Frazier Life Sciences Management L.P. owned about 1.80% of Immatics worth $15,272,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Bank of America Corp DE raised its position in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after buying an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Immatics by 34.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after acquiring an additional 2,479 shares during the last quarter. Guggenheim Capital LLC acquired a new position in Immatics during the fourth quarter valued at approximately $101,000. Forefront Analytics LLC lifted its stake in Immatics by 42.3% during the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after purchasing an additional 4,731 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new stake in Immatics during the fourth quarter worth $130,000. 64.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen downgraded Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday. Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a research note on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.00.

Immatics Trading Down 1.7%

IMTX stock traded down $0.09 during mid-day trading on Monday, reaching $5.11. The company's stock had a trading volume of 375,092 shares, compared to its average volume of 653,124. Immatics has a 12 month low of $3.30 and a 12 month high of $13.77. The business's 50 day moving average price is $4.52 and its 200 day moving average price is $5.68. The company has a market cap of $621.12 million, a price-to-earnings ratio of -7.74 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. As a group, equities analysts expect that Immatics will post -0.72 EPS for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.